Free Trial

Mattel (MAT) FDA Events

Mattel logo
$20.14 +0.05 (+0.25%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$20.13 -0.01 (-0.04%)
As of 07/9/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
FDA Events for Mattel (MAT)

This section highlights FDA-related milestones and regulatory updates for drugs developed by Mattel (MAT). Over the past two years, Mattel has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Barbie. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

Barbie - FDA Regulatory Timeline and Events

Barbie is a drug developed by Mattel for the following indication: type 1 diabetes (T1D). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Mattel FDA Events - Frequently Asked Questions

As of now, Mattel (MAT) has not received any FDA approvals for its therapy in the last two years.

In the past two years, Mattel (MAT) has reported FDA regulatory activity for Barbie.

The most recent FDA-related event for Mattel occurred on July 8, 2025, involving Barbie. The update was categorized as "Provided Update," with the company reporting: "Mattel, Inc announced that Barbie® is debuting the first Barbie doll with type 1 diabetes (T1D)."

Currently, Mattel has one therapy (Barbie) targeting the following condition: type 1 diabetes (T1D).

More FDA Event Resources from MarketBeat

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

This page (NASDAQ:MAT) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners